Abstract:Cardiovascular diseases are the most important cause of morbidity and mortality in the civilized world. Stenosis or occlusion of blood vessels leads not only to events that are directly life-threatening, such as myocardial infarction or stroke, but also to a significant reduction in quality of life, for example in lower limb ischemia as a consequence of metabolic diseases. The first synthetic polymeric vascular replacements were used clinically in the early 1950s. However, they proved to be suitable only for larger-diameter vessels, where the blood flow prevents the attachment of platelets, pro-inflammatory cells and smooth muscle cells on their inner surface, whereas in smaller-diameter grafts (6 mm or less), these phenomena lead to stenosis and failure of the graft. Moreover, these polymeric vascular replacements, like biological grafts (decellularized or devitalized), are cell-free, i.e. there are no reconstructed physiological layers of the blood vessel wall, i.e. an inner layer of endothelial cells to prevent thrombosis, a middle layer of smooth muscle cells to perform the contractile function, and an outer layer to provide innervation and vascularization of the vessel wall. Vascular substitutes with these cellular components can be constructed by tissue engineering methods. However, it has to be admitted that even about 70 years after the first polymeric vascular prostheses were implanted into human patients, there are still no functional small-diameter vascular grafts on the market. The damage to small-diameter blood vessels has to be addressed by endovascular approaches or by autologous vascular substitutes, which leads to some skepticism about the potential of tissue engineering. However, new possibilities of this approach lie in the use of modern technologies such as 3D bioprinting and/or electrospinning in combination with stem cells and pre-vascularization of tissue-engineered vascular grafts. In this endeavor, sex-related differences in the removal of degradable biomaterials by the cells and in the behavior of stem cells and pre-differentiated vascular cells need to be taken into account.

Overcoming big bottlenecks in vascular regeneration

Bioengineering Human Tissues and the Future of Vascular Replacement

Advances in three-dimensional bioprinted stem cell-based tissue engineering for cardiovascular regeneration

Biomimetic Approaches in Scaffold-Based Blood Vessel Tissue Engineering

Advancing cardiac regeneration through 3D bioprinting: methods, applications, and future directions

Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease

Current Progress in Vascular Engineering and Its Clinical Applications

Cells And Vascular Tissue Engineering

[3D bioprinting: classification, evaluation, and application in vascular tissue engineering]

3D printing of biomaterials for vascularized and innervated tissue regeneration

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts

Therapeutic Angiogenesis and Tissue Revascularization in Ischemic Vascular Disease

3D printing of tissue engineering scaffolds: a focus on vascular regeneration

Application of stem cells in engineered vascular graft and vascularized organs

Cellular Based Strategies for Microvascular Engineering

Vascular Damage and Repair - Are Small-Diameter Vascular Grafts Still the “Holy Grail” of Tissue Engineering?

Functional regeneration at the blood-biomaterial interface

State of the field: cellular and exosomal therapeutic approaches in vascular regeneration

Rebuilding the Vascular Network: In vivo and in vitro Approaches

Technology for the formation of engineered microvascular network models and their biomedical applications